341 related articles for article (PubMed ID: 31063970)
1. Tetrac as an anti-angiogenic agent in cancer.
Schmohl KA; Nelson PJ; Spitzweg C
Endocr Relat Cancer; 2019 Jun; 26(6):R287-R304. PubMed ID: 31063970
[TBL] [Abstract][Full Text] [Related]
2. Integrin αvβ3-Mediated Effects of Thyroid Hormones on Mesenchymal Stem Cells in Tumor Angiogenesis.
Schmohl KA; Mueller AM; Dohmann M; Spellerberg R; Urnauer S; Schwenk N; Ziegler SI; Bartenstein P; Nelson PJ; Spitzweg C
Thyroid; 2019 Dec; 29(12):1843-1857. PubMed ID: 31816265
[No Abstract] [Full Text] [Related]
3. Thyroid hormones and tetrac: new regulators of tumour stroma formation via integrin αvβ3.
Schmohl KA; Müller AM; Wechselberger A; Rühland S; Salb N; Schwenk N; Heuer H; Carlsen J; Göke B; Nelson PJ; Spitzweg C
Endocr Relat Cancer; 2015 Dec; 22(6):941-52. PubMed ID: 26307023
[TBL] [Abstract][Full Text] [Related]
4. Thyroid Hormone Effects on Mesenchymal Stem Cell Biology in the Tumour Microenvironment.
Schmohl KA; Müller AM; Nelson PJ; Spitzweg C
Exp Clin Endocrinol Diabetes; 2020 Jun; 128(6-07):462-468. PubMed ID: 31648351
[TBL] [Abstract][Full Text] [Related]
5. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor.
Mousa SA; Bergh JJ; Dier E; Rebbaa A; O'Connor LJ; Yalcin M; Aljada A; Dyskin E; Davis FB; Lin HY; Davis PJ
Angiogenesis; 2008; 11(2):183-90. PubMed ID: 18080776
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of pathological retinal angiogenesis by the integrin αvβ3 antagonist tetraiodothyroacetic acid (tetrac).
Yoshida T; Gong J; Xu Z; Wei Y; Duh EJ
Exp Eye Res; 2012 Jan; 94(1):41-8. PubMed ID: 22123068
[TBL] [Abstract][Full Text] [Related]
7. Actions of L-thyroxine (T4) and Tetraiodothyroacetic Acid (Tetrac) on Gene Expression in Thyroid Cancer Cells.
Davis PJ; Lin HY; Hercbergs A; Mousa SA
Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32645835
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancer.
Rajabi M; Yalcin M; Mousa SA
Bioorg Med Chem Lett; 2018 Apr; 28(7):1223-1227. PubMed ID: 29519736
[TBL] [Abstract][Full Text] [Related]
9. Cancer Cell Gene Expression Modulated from Plasma Membrane Integrin αvβ3 by Thyroid Hormone and Nanoparticulate Tetrac.
Davis PJ; Glinsky GV; Lin HY; Leith JT; Hercbergs A; Tang HY; Ashur-Fabian O; Incerpi S; Mousa SA
Front Endocrinol (Lausanne); 2014; 5():240. PubMed ID: 25628605
[TBL] [Abstract][Full Text] [Related]
10. Thyroid hormone induced angiogenesis through the integrin αvβ3/protein kinase D/histone deacetylase 5 signaling pathway.
Liu X; Zheng N; Shi YN; Yuan J; Li L
J Mol Endocrinol; 2014 Jun; 52(3):245-54. PubMed ID: 24532656
[TBL] [Abstract][Full Text] [Related]
11. Identification and functions of the plasma membrane receptor for thyroid hormone analogues.
Lin HY; Cody V; Davis FB; Hercbergs AA; Luidens MK; Mousa SA; Davis PJ
Discov Med; 2011 Apr; 11(59):337-47. PubMed ID: 21524387
[TBL] [Abstract][Full Text] [Related]
12. Thyroid hormone and angiogenesis.
Luidens MK; Mousa SA; Davis FB; Lin HY; Davis PJ
Vascul Pharmacol; 2010; 52(3-4):142-5. PubMed ID: 19879961
[TBL] [Abstract][Full Text] [Related]
13. Membrane receptor for thyroid hormone: physiologic and pharmacologic implications.
Davis PJ; Davis FB; Mousa SA; Luidens MK; Lin HY
Annu Rev Pharmacol Toxicol; 2011; 51():99-115. PubMed ID: 20868274
[TBL] [Abstract][Full Text] [Related]
14. Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts.
Yalcin M; Bharali DJ; Lansing L; Dyskin E; Mousa SS; Hercbergs A; Davis FB; Davis PJ; Mousa SA
Anticancer Res; 2009 Oct; 29(10):3825-31. PubMed ID: 19846915
[TBL] [Abstract][Full Text] [Related]
15. Thyroid Hormone, Hormone Analogs, and Angiogenesis.
Davis PJ; Sudha T; Lin HY; Mousa SA
Compr Physiol; 2015 Dec; 6(1):353-62. PubMed ID: 26756636
[TBL] [Abstract][Full Text] [Related]
16. Nongenomic Actions of Thyroid Hormone: The Integrin Component.
Davis PJ; Mousa SA; Lin HY
Physiol Rev; 2021 Jan; 101(1):319-352. PubMed ID: 32584192
[TBL] [Abstract][Full Text] [Related]
17. Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid.
Yalcin M; Dyskin E; Lansing L; Bharali DJ; Mousa SS; Bridoux A; Hercbergs AH; Lin HY; Davis FB; Glinsky GV; Glinskii A; Ma J; Davis PJ; Mousa SA
J Clin Endocrinol Metab; 2010 Apr; 95(4):1972-80. PubMed ID: 20133461
[TBL] [Abstract][Full Text] [Related]
18. The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin.
Mousa SA; O'Connor LJ; Bergh JJ; Davis FB; Scanlan TS; Davis PJ
J Cardiovasc Pharmacol; 2005 Sep; 46(3):356-60. PubMed ID: 16116342
[TBL] [Abstract][Full Text] [Related]
19. Integrin αvβ3-dependent thyroid hormone effects on tumour proliferation and vascularisation.
Schmohl KA; Han Y; Tutter M; Schwenk N; Sarker RSJ; Steiger K; Ziegler SI; Bartenstein P; Nelson PJ; Spitzweg C
Endocr Relat Cancer; 2020 Dec; 27(12):685-697. PubMed ID: 33112795
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of MR-49, a deiodinated analog of tetraiodothyroacetic acid (tetrac), as a novel pro-angiogenesis modulator.
Rajabi M; Sudha T; Darwish NH; Davis PJ; Mousa SA
Bioorg Med Chem Lett; 2016 Aug; 26(16):4112-6. PubMed ID: 27381084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]